Epidermal growth factor receptor cell proliferation signaling pathways

P Wee, Z Wang - Cancers, 2017 - mdpi.com
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001–2011)

J Wang, M Sánchez-Roselló, JL Aceña… - Chemical …, 2014 - ACS Publications
1.1. Brief Historical Overview As expected from the fluorine position on the periodic table of
elements, it possesses some extreme properties, in particular, ultimate electronegativity and …

Emerging functions of the EGFR in cancer

S Sigismund, D Avanzato, L Lanzetti - Molecular oncology, 2018 - Wiley Online Library
The physiological function of the epidermal growth factor receptor (EGFR) is to regulate
epithelial tissue development and homeostasis. In pathological settings, mostly in lung and …

Small molecule kinase inhibitor drugs (1995–2021): medical indication, pharmacology, and synthesis

CC Ayala-Aguilera, T Valero… - Journal of Medicinal …, 2021 - ACS Publications
The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer

PT Harrison, S Vyse, PH Huang - Seminars in cancer biology, 2020 - Elsevier
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

The ErbB/HER family of protein-tyrosine kinases and cancer

R Roskoski Jr - Pharmacological research, 2014 - Elsevier
The human epidermal growth factor receptor (EGFR) family consists of four members that
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …

Screening for epidermal growth factor receptor mutations in lung cancer

R Rosell, T Moran, C Queralt, R Porta… - … England Journal of …, 2009 - Mass Medical Soc
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …

FDA-approved small-molecule kinase inhibitors

P Wu, TE Nielsen, MH Clausen - Trends in pharmacological sciences, 2015 - cell.com
Kinases have emerged as one of the most intensively pursued targets in current
pharmacological research, especially for cancer, due to their critical roles in cellular …

Mechanisms of receptor tyrosine kinase activation in cancer

Z Du, CM Lovly - Molecular cancer, 2018 - Springer
Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …

Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors

Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez… - Nature, 2016 - nature.com
The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs)
gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers …